

# CONTENTS

---

<b>Preface</b>	<b>ix</b>
<b>Acknowledgments</b>	<b>xi</b>
<b>1 Introduction</b>	<b>1</b>
1.1 Origin and preparation of drugs	3
1.2 Drugs and drug targets	4
1.3 Drug molecules may or may not resemble the physiological ligands of their receptors	7
1.4 Strategies of drug discovery and development	11
References	14
<b>2 Pharmacodynamics</b>	<b>15</b>
2.1 Molecular features of drug-receptor interaction	15
2.2 Theory of drug-receptor binding	17
2.3 Dose-effect relationships in signaling cascades	25
2.4 Potency and efficacy	28
2.5 Beneficial and toxic drug effects	28
2.6 Appendix	30
Study questions	35
References	36
	<b>v</b>

<b>3</b>	<b>Pharmacokinetics</b>	<b>37</b>
3.1	Anatomical barriers to drug transport	38
3.2	Solute transport across cell membranes	40
3.3	Drug application	49
3.4	Drug distribution	53
3.5	Drug elimination via the kidneys	56
3.6	Quantitative experimental methods in pharmacokinetics	63
	Study questions	65
	References	65
<b>4</b>	<b>Drug metabolism</b>	<b>67</b>
4.1	Overview: Possible functional outcomes of drug metabolism	68
4.2	Phase I and phase II reactions	70
4.3	Cytochrome P450	71
4.4	Reductive drug metabolism	74
4.5	Conjugation reactions	75
4.6	Enzyme induction	83
4.7	Metabolism-related toxicity as a therapeutic target	84
	Study questions	85
	References	85
<b>5</b>	<b>G protein-coupled receptors</b>	<b>87</b>
5.1	Overview	87
5.2	GPCR structure	89
5.3	Structural GPCR families	89
5.4	Activation of GPCRs	90
5.5	GPCR dimerization and oligomerization	96
5.6	G proteins	98
5.7	GPCR phosphorylation, endocytosis, and G protein-independent signaling	102
5.8	Appendix	103
	Study questions	107
	References	108
<b>6</b>	<b>Pharmacology of cell excitation</b>	<b>111</b>
6.1	Ions, pumps, and channels	114
6.2	ATP-driven active ion transport	116
6.3	Voltage-gated channels and the action potential	116
6.4	Channels controlled by intracellular ligands	120
6.5	Transient receptor potential (TRP) channels	120
6.6	Voltage-gated channels of nerve cells as drug targets	121
6.7	Synaptic transmission	127
6.8	Pharmacology of individual transmitters	136
6.9	Appendix	153
	Study questions	160
	References	161

<b>7</b>	<b>Hormones</b>	<b>163</b>
7.1	Hormone receptors	164
7.2	The hypothalamus and the pituitary gland	164
7.3	Thyroid gland hormones	170
7.4	Steroid hormones	175
7.5	Endocrine control of bone mineralization	183
	Study questions	188
	References	189
<b>8</b>	<b>Pharmacology of nitric oxide</b>	<b>191</b>
8.1	Characterization of nitric oxide as a biological signaling molecule	192
8.2	Nitric oxide synthase and its isoforms	192
8.3	Biochemical mechanisms of NO signaling	195
8.4	The biological function of iNOS	200
8.5	NO-releasing drugs	200
8.6	NOS inhibitors	204
8.7	Phosphodiesterase inhibitors	204
	Study questions	205
	References	205
<b>9</b>	<b>Eicosanoid mediators and related drugs</b>	<b>207</b>
9.1	Biosynthesis of eicosanoids	208
9.2	The cyclooxygenase reaction	211
9.3	Cyclooxygenase isoforms and inhibitors	211
9.4	Phospholipase A <sub>2</sub> inhibitors	217
9.5	Derivatives of prostaglandin H <sub>2</sub> and related drugs	217
9.6	Lipoxygenases, leukotrienes, and related drugs	218
9.7	Eicosanoids synthesized by cytochrome P450	219
9.8	Endocannabinoids and related drugs	219
9.9	The role of polyunsaturated fatty acids in eicosanoid signaling	223
	Study questions	224
	References	224
<b>10</b>	<b>Intermediate metabolism, diabetes and atherosclerosis</b>	<b>227</b>
10.1	Hereditary enzyme defects	227
10.2	Gout	235
10.3	Diabetes mellitus	238
10.4	Atherosclerosis	241
	Study questions	251
	References	252
<b>11</b>	<b>Chemotherapy of infectious diseases</b>	<b>255</b>
11.1	Pathogenic microbes: Diversity and selective toxicity	256
11.2	Pharmacokinetic considerations	257

11.3	Resistance to antimicrobials	258
11.4	Antibacterial chemotherapy	259
11.5	Chemotherapy of fungal infections	277
11.6	Chemotherapy of parasite infections	279
11.7	Antiviral chemotherapy	284
	Study questions	291
	References	292
<b>12</b>	<b>Tumor chemotherapy</b>	<b>295</b>
12.1	Some principles of tumor biology	296
12.2	Cell-type-specific antitumor drugs	304
12.3	Drugs that target specific oncoproteins	306
12.4	Cytotoxic antitumor drugs	309
	Study questions	320
	References	320
<b>13</b>	<b>Ribonucleic acids as drug targets and drugs</b>	<b>323</b>
13.1	RNA as drug target	324
13.2	RNA as a therapeutic agent	336
	Study questions	339
	References	339
<b>14</b>	<b>Drug delivery</b>	<b>343</b>
14.1	Improving intestinal drug absorption	343
14.2	Improving drug distribution	348
14.3	Targeted drug delivery	352
14.4	Kinetically controlled drug release	358
14.5	Controlling drug toxicity	363
14.6	Delivery of nucleic acids	367
	Study questions	368
	References	368
<b>15</b>	<b>Drug discovery</b>	<b>373</b>
15.1	Target selection and validation	373
15.2	Screening of candidate compounds	375
15.3	Computational screening	381
15.4	Phenotypic screening	384
15.5	Compound acquisition	384
	Study questions	389
	References	389
	<b>Answers to study questions</b>	<b>393</b>
	References	400
	<b>Index</b>	<b>403</b>